Vimarsana
Biggest News Aggregation in the World

Page 38 - Stem Cell Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Stem Cell Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Stem Cell Therapy Today - Breaking & Trending Today

Using JAK Inhibitors for Myelofibrosis - Vimarsana News

Using JAK Inhibitors for Myelofibrosis

"We are thankfully starting to be blessed with more options than we've ever had," but "in the frontline proliferative setting, ruxolitinib has remained the standard of care."

Stem cell therapy for macular degeneration - Vimarsana News

Stem cell therapy for macular degeneration

Explore the current landscape of AMD cell therapy, future prospects and challenges for this exciting emerging technology

Therapeutic Solutions International Reports Landmark Advancement in Stem Cell Therapy of Frontotemporal Dementia - Vimarsana News

Therapeutic Solutions International Reports Landmark Advancement in Stem Cell Therapy of Frontotemporal Dementia

ELK CITY, Idaho, September 11, 2023--Therapeutic Solutions International, Inc. (TSOI), announced today the development of a new therapeutic approach for treatment of Frontotemporal Dementia, by combining the activation of endogenous anti-inflammatory cells in the nervous system, together with regenerative cell intervention in the form of stem cell therapy, and molecules capable of activating endogenous stem cells already present in the patient.

Source: yahoo.com
FDA OKs Motixafortide for Stem Cell Mobilization in Myeloma - Vimarsana News

FDA OKs Motixafortide for Stem Cell Mobilization in Myeloma

The GENESIS trial reported substantially better stem cell mobilization when patients with multiple myeloma received motixafortide alongside filgrastim.

Is Additional Treatment Needed Pretransplant in R/R AML? - Vimarsana News

Is Additional Treatment Needed Pretransplant in R/R AML?

Experts recently debated whether additional intensive therapy can improve posttransplant outcomes for patients with acute myeloid leukemia who have residual disease after induction therapy.